Mar 27 |
Panbela Therapeutics, Inc. (PBLA) Q4 2023 Earnings Call Transcript
|
Mar 26 |
Panbela Therapeutics GAAP EPS of -$65.90 beats by $151.10
|
Mar 26 |
Panbela Provides Business Update and Reports Q4 and FY 2024 Financial Results
|
Mar 12 |
Panbela to Host Fourth Quarter and Year End 2023 Earnings Conference Call on March 26, 2024
|
Feb 23 |
Top 4 Health Care Stocks That Are Preparing To Pump This Month
|
Feb 15 |
Panbela Therapeutics regains compliance with Nasdaq
|
Feb 15 |
Panbela Regains Compliance with Nasdaq Listing Standards for Bid Price and Publicly Held Shares Requirements
|
Feb 1 |
Panbela Therapeutics closes ~$9M public offering of shares
|
Feb 1 |
Panbela Announces Closing of Approximately $9.0 Million Public Offering
|
Jan 30 |
Acceptance of Ivospemin (SBP-101) Abstract for Poster Presentation at American Association for Cancer Research (AACR)
|